Pancreatic Cancer Research

ResearcherGuy's HospitalActive in the last 2 years

Debashis Sarker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4814-8429; OpenAlex author ID A5089670001. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 17

  1. Associations Between Routinely Measured Biomarkers and Pancreatic Cancer Risk in Individuals with Type 2 Diabetes Pre- and Post-Diagnosis. Co-author DOI 10.3390/cancers18091428↗
  2. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  3. Targeted Sequencing of Pancreatic Ductal Adenocarcinoma Tissue Co-author DOI 10.1101/2023.01.13.523431↗
  4. CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adi0244↗
  5. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Co-author DOI 10.1038/s41467-022-29684-9↗
  6. Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I study. Co-author DOI 10.1016/j.ejso.2021.05.024↗
  7. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts. Co-author DOI 10.3390/cells10071653↗
  8. Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. Co-author DOI 10.3390/jcm10081665↗
  9. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Co-author DOI 10.1038/s41467-020-18636-w↗
  10. Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Co-author DOI 10.3389/fonc.2020.00263↗
  11. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. Co-author DOI 10.1186/s12885-019-6082-6↗
  12. PAK4 pathway as a potential therapeutic target in pancreatic cancer. First author DOI 10.2217/fon-2017-0458↗
  13. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  14. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Co-author DOI 10.18632/oncotarget.13309↗
  15. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. First author DOI 10.3109/08923973.2015.1100204↗
  16. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. Co-author DOI 10.1371/journal.pone.0090948↗
  17. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Last author DOI 10.1586/14737140.2014.957188↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mieke Van Hemelrijck · 4 shared papers, 2019–2026 · strength 0.65
  2. Aida Santaolalla · 4 shared papers, 2019–2026 · strength 0.65
  3. Claire M. Wells · 4 shared papers, 2017–2023 · strength 0.61
  4. Hemant Mahendrakumar Kocher · 4 shared papers, 2018–2025 · strength 0.46
  5. Kiruthikah Thillai · 4 shared papers, 2014–2021 · strength 0.45
  6. Pilar Acedo Núñez · 1 shared paper, 2026 · strength 0.30
  7. Ziying Zhang · 1 shared paper, 2026 · strength 0.30
  8. David J. Propper · 2 shared papers, 2020–2025 · strength 0.28
  9. Christine Hughes · 2 shared papers, 2020–2025 · strength 0.28
  10. Fieke E. M. Froeling · 2 shared papers, 2020–2025 · strength 0.28
  11. Yoh Zen · 3 shared papers, 2014–2022 · strength 0.26
  12. Kiruthikah Thailli · 1 shared paper, 2023 · strength 0.24
  13. Christian Benzing · 1 shared paper, 2023 · strength 0.24
  14. Andreas A. Prachalias · 2 shared papers, 2021–2022 · strength 0.23
  15. Claude Chelala · 1 shared paper, 2025 · strength 0.19
  16. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19
  17. David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.19
  18. Mairead Geraldine McNamara · 1 shared paper, 2025 · strength 0.19
  19. Pippa G. Corrie · 1 shared paper, 2025 · strength 0.19
  20. Dominique S. Michaud · 2 shared papers, 2019–2020 · strength 0.19
  21. Sam Sollie · 2 shared papers, 2019–2020 · strength 0.19
  22. Ester Pfeifer · 1 shared paper, 2021 · strength 0.17
  23. Richard Beatson · 1 shared paper, 2021 · strength 0.17
  24. Joy Burchell · 1 shared paper, 2021 · strength 0.17
  25. Paul J. Ross · 2 shared papers, 2014–2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.